COMMUNIQUÉS West-GlobeNewswire

SeaStar Medical Reports Statistically Significant Survival Findings from Post-Approval QUELIMMUNE® SAVE Registry Analysis in Pediatric Sepsis-Associated AKI
22/10/2026
New late-breaking data presented today at ASN Kidney Week 2026 QUELIMMUNE (SCD-PED) treatment group demonstrates statistically significant higher survival in the primary analysis at Day 60, Day 90, and at hospital [...]
Walden Biosciences Announces Positive Data from Diabetic Kidney Disease Cohorts in Ongoing Phase 2 Study of WAL0921
22/10/2026
Six of 12 evaluable participants receiving WAL0921 treatment experienced proteinuria (UACR) reduction greater than 20 percent; median 32.4 percent UACR reduction among responders Initial clinical results provide proof- [...]
InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026
22/10/2026
Data from pre-clinical renal disease models demonstrate potential of izicopan for kidney protection Structural modeling provides new insight into izicopan’s differentiated molecular profile Jena, Germany, Oct. 22, 2026 [...]
Regulated information: Disclosure of a transparency notification from Aberdeen Group plc
22/10/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 22 October 2026 – 6 PM CET Disclosure of a transparency notification from Aberdeen Group plc Pursuant to the Belgian act of 2 May 2007 on the [...]
One04 Therapeutics presents positive interim Phase 1 data for CPV-104 in C3 glomerulopathy in ASN Kidney Week late-breaker
22/10/2026
Met predefined primary and secondary objectives for the interim analysis CPV-104 was generally well tolerated in healthy volunteers and patients with C3 glomerulopathy (C3G) Exploratory analyses in patients with C3G [...]
Guerbet : Chiffre d’affaires au 30 septembre 2026.
22/10/2026
Chiffre d’affaires au 30 septembre 2026 Une activité conforme aux anticipations du Groupe Chiffre d’affaires au 30 septembre 2026 de 573,8 M€, en repli de 1,3% à TCC 1 et périmètre comparable 2 ; hors Chine, une [...]
Guerbet : Revenue at 30 September 2026.
22/10/2026
Revenue at 30 September 2026 Business in line with Group expectations Revenue at 30 September 2026 of €573.8m, down 1.3% at CER 1 and like-for-like 2 ; excluding China, business grew by 1%, with a positive contribution [...]
Alignment Health Adds New Medicare Advantage Plan in Pima County, Increasing Access and Choice for Arizona Seniors
22/10/2026
New plan strengthens Alignment’s Arizona portfolio available to nearly 1.1 million Medicare beneficiaries across Maricopa, Pima and Santa Cruz counties PHOENIX, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Alignment Health Plan, [...]
Promaxo Announces Closing of Series C Financing and $100M Credit Facility
22/10/2026
The growth capital will expand manufacturing capacity, reduce backlog, and support new regulatory filings OAKLAND, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Promaxo today announced the initial close of its Series C [...]
SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome
22/10/2026
TEL AVIV, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage [...]
Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment
22/10/2026
Leadership discusses recent FDA engagement, the technology underlying ERNA-101 and the development strategy supporting planned first-in-human clinical evaluation Discussion features Sanjeev Luther, President and Chief [...]
BreathiZen Introduces BreathiZen Spray - A New Multi-Ingredient Dietary Supplement For Your Respiratory Wellness
22/10/2026
BreathiZen is a once-daily oral spray that brings together botanical extracts, an enzyme preparation, and selected nutrients in a 60 ml bottle designed to fit easily into an adult wellness routine. New York, Oct. 22, [...]
ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update
22/10/2026
WINSTON-SALEM, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today [...]
RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
22/10/2026
Company to host conference call on November 5, 2026, at 4:30 p.m. ET MOUNTAIN VIEW, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company [...]
Vericel to Report Third Quarter 2026 Financial Results on November 5, 2026
22/10/2026
BURLINGTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report [...]
Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea
22/10/2026
- MOU relates to a potential clinical trial in South Korea, Alpha DaRT’s first, at Samsung Medical Center (SMC) in Seoul, ranked fifth in the world and number one in Korea in oncology - - In Korea, only about one in [...]
ICU Medical Announces Time of Third Quarter 2026 Earnings Conference Call
22/10/2026
SAN CLEMENTE, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its third quarter [...]
Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day
22/10/2026
VANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
22/10/2026
Clears Pathway for Execution of Future R&D Milestone Events such as the Phase 1b, FIH Study for PRP in up to 50 Advanced Cancer Patients with Solid Tumors, First Quarter, 2027 MELBOURNE, Australia, Oct. 22, 2026 ( [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum